{"id":"daclatasvir-sofosbuvir","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL2303621","moleculeType":"Small molecule","molecularWeight":"811.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daclatasvir is an NS5A inhibitor that prevents viral protein complex formation and RNA replication. Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase, blocking viral RNA synthesis. Together, this combination directly targets two essential HCV replication enzymes, achieving high cure rates across multiple HCV genotypes.","oneSentence":"Daclatasvir and sofosbuvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5A protein and the NS5B RNA polymerase, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:54.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes"}]},"trialDetails":[{"nctId":"NCT05992077","phase":"NA","title":"Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-08-07","conditions":"HCV Infection","enrollment":21000},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT04943588","phase":"","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-11-01","conditions":"Hepatitis C, Chronic","enrollment":25000},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT05854511","phase":"PHASE3","title":"Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-06-05","conditions":"HCV","enrollment":30},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03540212","phase":"PHASE2, PHASE3","title":"Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-12-10","conditions":"Chronic HCV Infection","enrollment":50},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT04852614","phase":"","title":"Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT04561063","phase":"PHASE2","title":"COVID-19 Prophylaxis South Africa (COVER HCW)","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-08","conditions":"Covid19, SARS-CoV Infection","enrollment":1950},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT03706898","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-10-01","conditions":"HIV-1-infection, Hepatic Impairment","enrollment":36},{"nctId":"NCT03158857","phase":"","title":"Hepatitis C Treatment Study in Myanmar","status":"WITHDRAWN","sponsor":"Myanmar Oxford Clinical Research Unit","startDate":"2022-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT05138523","phase":"","title":"Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2019-11-21","conditions":"Chronic Hepatitis c","enrollment":99},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT03487848","phase":"PHASE2","title":"Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-06-25","conditions":"Hepatitis C, Chronic Hepatitis","enrollment":5},{"nctId":"NCT03883698","phase":"PHASE3","title":"Safety of Sofosbuvir in People With Advanced Kidney Failure","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2019-03-15","conditions":"Kidney Failure, Chronic, Hepatitis C","enrollment":30},{"nctId":"NCT04773756","phase":"PHASE4","title":"Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-11-01","conditions":"Covid19","enrollment":54},{"nctId":"NCT04535869","phase":"PHASE3","title":"Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-12-28","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04113629","phase":"NA","title":"Simplified Monitoring Myanmar SM2 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-01-22","conditions":"Hepatitis C, Liver Cirrhoses, Liver Inflammation","enrollment":200},{"nctId":"NCT03669835","phase":"NA","title":"The Sublimated Mare Milk Supplement in Hepatitis C","status":"COMPLETED","sponsor":"Asfendiyarov Kazakh National Medical University","startDate":"2018-03-28","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT04729153","phase":"","title":"Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02","conditions":"Covid19","enrollment":100},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04460443","phase":"PHASE2, PHASE3","title":"Sofosbuvir in Treatment of COVID 19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-08-01","conditions":"COVID","enrollment":60},{"nctId":"NCT04497649","phase":"PHASE2, PHASE3","title":"Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-07-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT03283176","phase":"","title":"Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals","enrollment":50},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04443725","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-07","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04387526","phase":"PHASE2, PHASE3","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2016-04-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":946},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT04122066","phase":"","title":"the Pulmonary Safety of Antihepatitis C Treatment","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT04244383","phase":"PHASE4","title":"Expression of Inflammasomes in HCV Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03166943","phase":"NA","title":"the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-05-10","conditions":"Hepatitis","enrollment":130},{"nctId":"NCT04211844","phase":"","title":"Metabolic Changes in Chronic HCV Patients Receiving DAAS","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT04159246","phase":"","title":"Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C","status":"UNKNOWN","sponsor":"Mohamed Saad","startDate":"2019-02-10","conditions":"HCV Infection","enrollment":30},{"nctId":"NCT03063879","phase":"PHASE4","title":"Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-04-01","conditions":"Hepatitis C, Chronic, Chronic Renal Failure","enrollment":95},{"nctId":"NCT03163849","phase":"PHASE3","title":"Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09-01","conditions":"Chronic Hepatitis c","enrollment":50},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03481036","phase":"NA","title":"DAA Therapy in Pediatric Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03369327","phase":"PHASE3","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-01-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus","enrollment":232},{"nctId":"NCT03200184","phase":"PHASE4","title":"Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2016-09-01","conditions":"Hepatitis C","enrollment":1448},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT03490097","phase":"PHASE2, PHASE3","title":"Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-12-01","conditions":"Chronic Hepatitis c, Metabolic Syndrome","enrollment":100},{"nctId":"NCT03665766","phase":"","title":"Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-05-15","conditions":"Liver Transplantation","enrollment":126},{"nctId":"NCT03646396","phase":"NA","title":"Effect of Sofosbuvir-daclatasuvir on Angiogenesis","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-08-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03480269","phase":"","title":"Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-08-01","conditions":"Predictors of Response to HCV Tretment","enrollment":100},{"nctId":"NCT03572140","phase":"","title":"Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"HCV","enrollment":297},{"nctId":"NCT03080415","phase":"PHASE3","title":"Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir","status":"COMPLETED","sponsor":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","startDate":"2017-03-18","conditions":"Hepatitis C Genotype 4","enrollment":40},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02673489","phase":"PHASE3","title":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-15","conditions":"Hepatitis C","enrollment":106},{"nctId":"NCT02576314","phase":"PHASE3","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05","conditions":"Chronic Hepatitis C Infection","enrollment":48},{"nctId":"NCT02482077","phase":"PHASE4","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":112},{"nctId":"NCT02473211","phase":"PHASE2, PHASE3","title":"SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":106},{"nctId":"NCT03186313","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Egyptian Liver Hospital","startDate":"2016-09","conditions":"Hepatitis C","enrollment":72},{"nctId":"NCT03169348","phase":"NA","title":"The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-11-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03318887","phase":"","title":"Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-02-01","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT02772744","phase":"","title":"Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2017-11-01","conditions":"Hepatitis C","enrollment":250},{"nctId":"NCT03296930","phase":"PHASE4","title":"Effect Of DAAs For Treatment Of HCV On Normal Kidney","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10-01","conditions":"Antiviral Drug Adverse Reaction","enrollment":100},{"nctId":"NCT02628717","phase":"","title":"Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":558},{"nctId":"NCT03268317","phase":"","title":"Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03247296","phase":"","title":"Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir","status":"UNKNOWN","sponsor":"MTI University","startDate":"2017-02-28","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT03241823","phase":"","title":"Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-01","conditions":"Hepatitis C, Liver Cirrhosis","enrollment":100},{"nctId":"NCT02624063","phase":"PHASE4","title":"Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT03226717","phase":"","title":"Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03188276","phase":"EARLY_PHASE1","title":"The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-02-01","conditions":"Chronic Hepatitis C","enrollment":52},{"nctId":"NCT03166280","phase":"","title":"Hepatitis c and Vitamin D and Iron Status","status":"UNKNOWN","sponsor":"Eman Sayed Hassan Abd Allah","startDate":"2017-06","conditions":"Hepatitis C","enrollment":87},{"nctId":"NCT02932293","phase":"PHASE2","title":"Triple Combination DAAs for Treating HCV GT1b Subjects","status":"WITHDRAWN","sponsor":"Humanity and Health Research Centre","startDate":"2016-12","conditions":"Chronic Hepatitis C Infection","enrollment":""},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT02349048","phase":"PHASE2","title":"Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Hepatitis C Virus","enrollment":68},{"nctId":"NCT03063723","phase":"","title":"Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Chronic Hepatitis C (Disorder)","enrollment":25},{"nctId":"NCT02657694","phase":"","title":"Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods","status":"UNKNOWN","sponsor":"FixHepC","startDate":"2015-07-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT02032875","phase":"PHASE3","title":"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT02319031","phase":"PHASE3","title":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-02","conditions":"Hepatitis C","enrollment":53},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02771405","phase":"PHASE3","title":"Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02531269","phase":"","title":"Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02161939","phase":"","title":"A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02097966","phase":"","title":"EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Chronic Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":72,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Solvaldi, Daklinza"],"phase":"marketed","status":"active","brandName":"Daclatasvir + Sofosbuvir","genericName":"Daclatasvir + Sofosbuvir","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daclatasvir and sofosbuvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5A protein and the NS5B RNA polymerase, respectively. Used for Chronic hepatitis C virus (HCV) infection, all genotypes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}